Fig. 5

Effect of EGFR targeted inhibitors on EMT-like changes in CYLD-knockdown OSCC cells. (A, E) SAS cells were treated with 5 μM gefitinib (A) and 10 µg/mL cetuximab (E), and Smad3 phosphorylation were assessed by immunoblotting. (B, F) Cell migration in SAS cells treated with 5 μM gefitinib (B) and 10 µg/mL cetuximab (F) was assessed by wound healing assay. (C, G) Cells were transfected with siRNA and then incubated for 48 h before being reseeded onto transwell insert. Cells were treated with 0.15 μM gefitinib (C) and 10 µg/mL cetuximab (G) for 24 h, and migrating cells were stained by crystal violet and then measured. D, H CYLD knockdown cells were treated with 5 μM gefitinib (D) and 10 µg/mL cetuximab (H) for 24 h, and Fibronectin mRNA expression was assessed by RT-qPCR. Scale bar shows 200 µm. Values are means ± S.D. of triplicate samples. **p < 0.01 in Tukey–Kramer method